DOCUMENT 07 · AUGUST 2026
Regulatory Classification Memorandum
Preliminary U.S. pathway analysis: FDA positioning, claims boundaries, research controls, and the staged regulatory decision plan. Prepared for planning and counsel review — not legal advice.
Preliminary conclusion
Classification cannot be determined from the hardware concept alone. FDA status will depend heavily on intended use, labeling, promotional claims, operating risk, and technical characteristics. A carefully bounded low-risk wellness launch may be possible, but electromagnetic therapeutic claims would likely place the product within medical-device regulation.
Recommended initial position
Develop the first commercial configuration around general wellbeing, relaxation, and a healthy-lifestyle experience only if regulatory counsel confirms the completed device is low risk. Do not state or imply diagnosis, treatment, cure, mitigation, prevention, pain relief, circulation improvement, muscle stimulation, or disease-specific benefit.
Why caution is required
FDA has cleared electromagnetic products for specific medical indications, and classification databases include electromagnetic and shortwave-diathermy device types. Similar technology, output characteristics, or therapeutic claims may make a broad wellness position difficult even when marketing language is restrained.
Research-platform position
Research-use positioning can support controlled studies and protocol development, but the words "research use" do not automatically remove FDA obligations. Distribution, labeling, sponsor responsibilities, human-subject protections, and commercial promotion must be reviewed for each study arrangement.
Future medical pathway
If a specific therapeutic indication is pursued, counsel should compare the final technology and intended use with legally marketed predicates. A 510(k) may be possible with substantial equivalence; a De Novo request may suit a novel low- or moderate-risk device without a suitable predicate.
Pathway comparison
| Position | Character | Key caution |
|---|---|---|
| A · General wellness | Possible only with general-wellness intended use and low risk; claims limited to maintaining or encouraging a general state of health. Fastest route, only if completed risk assessment and counsel support it. | Avoid medical imagery, clinical promises, treatment protocols, and testimonials implying therapeutic outcomes. |
| B · Research platform | Designed for controlled investigation, field characterization, and protocol studies. Supports evidence development without prematurely selecting a medical indication. | Do not market research availability as proof of safety, effectiveness, or authorization for clinical treatment. |
| C · Medical device | Disease- or condition-related indications after appropriate evidence and FDA pathway. | Likely requires formal design controls, quality systems, verification, clinical strategy, and premarket interaction. |
Claims & communications control
Lower-risk wellness language (for review)
✓ Supports a relaxing wellness experience
✓ Designed for use as part of a healthy lifestyle routine
✓ Provides configurable noninvasive electromagnetic-field sessions
✓ Allows operators to select documented session parameters
✓ Intended for general wellbeing only; not intended to diagnose, treat, cure, or prevent disease
Prohibited until supported by the appropriate pathway
✗ Treats pain, arthritis, neuropathy, inflammation, depression, insomnia, or any disease
✗ Improves circulation, heals tissue, accelerates recovery, or changes a physiologic condition
✗ FDA approved / certified / medically proven without precise authorization
✗ "Clinically proven" based on studies of other PEMF products or different parameters
✗ Safe for everyone, no contraindications, zero risk, or compatible with all implants
Communication governance
One approved claims library covering the website, pitch decks, sales scripts, training, presets, testimonials, social media, and distributor materials — with written regulatory approval for every new benefit statement and dated versions. Product names, preset names, and testimonials are claims and follow the same review process as formal labeling.
Safety communication
Develop contraindication, implanted-device, pregnancy, seizure-risk, emergency-stop, and adverse-event language with qualified clinical and engineering advisors. Electromagnetic products have presented implanted-device interaction concerns in FDA records.
Regulatory work plan
- Claims workshop — define the exact initial intended use, users, setting, claims, contraindications, and promotional boundaries.
- Classification assessment — search FDA classifications, product codes, 510(k)s, De Novo decisions, and enforcement history relevant to the final technology.
- Risk and technology review — document output range, waveform, field mapping, exposure, thermal behavior, implanted-device interaction, electrical safety, EMC, and foreseeable misuse.
- FDA interaction decision — determine whether a formal Q-Submission or other FDA interaction is appropriate before expensive verification or clinical work.
- Quality and evidence plan — select the quality-system, design-control, software, cybersecurity, human-factors, and evidence requirements appropriate to the chosen pathway.
- Launch gate — approve final labeling, website, instructions, training, complaint handling, adverse-event procedures, and distributor controls before sale.
Recommended immediate action
Retain experienced medical-device regulatory counsel to issue a written classification opinion based on the proposed hardware, output envelope, intended use, and exact claims — before finalizing the prototype requirements or investor statements.
Official FDA references: General Wellness: Policy for Low Risk Devices (final guidance, Jan. 6, 2026) · How to Determine if Your Product is a Medical Device · Premarket Notification 510(k) · De Novo Classification Request · FDA Product Classification Database (fda.gov)